Osteoporosis in mineral and bone disorders of chronic kidney disease

Polskie Archiwum Medycyny Wewnetrznej

Volumn 123, Issue 6, 2013, Pages 314-320

  Stompór, Tomasz ^a   Zablocki, Marek ^b   Lesiów, Miroslaw ^b  

^a UNIVERSITY OF WARMIA AND MAZURY IN OLSZTYN   (Poland)

^b Olsztyn Municipal Hospital   (Poland)

Author keywords

Bisphosphonates; Bone and mineral disorders of chronic kidney disease; Denosumab; Menopause; Osteoporosis

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB; ESTRADIOL PLUS NORETHISTERONE ACETATE; ESTROGEN; IBANDRONIC ACID; MINERAL; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; RISEDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID;

ACUTE KIDNEY FAILURE; BLOOD VESSEL CALCIFICATION; BONE DENSITY; BONE METASTASIS; CHRONIC KIDNEY DISEASE; CORONARY ARTERY CALCIFICATION; DRUG EFFICACY; DRUG EXCRETION; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; FRACTURE; FRAGILITY FRACTURE; GLOMERULUS FILTRATION RATE; HIP FRACTURE; HUMAN; KIDNEY FAILURE; METABOLIC BONE DISEASE; MULTIPLE MYELOMA; NONHUMAN; OSTEOPOROSIS; OUTCOME ASSESSMENT; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; SPINE FRACTURE; TRANSDERMAL PATCH; UNSPECIFIED SIDE EFFECT; COMORBIDITY; EPIDEMIOLOGY; FRACTURES, BONE; PATHOPHYSIOLOGY; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT;

CAUSALITY; COMORBIDITY; FRACTURES, BONE; GLOMERULAR FILTRATION RATE; HUMANS; OSTEOPOROSIS; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT;

EID: 84882943363     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.1782     Document Type: Review

References (49)

1. Matuszkiewicz-Rowińska J. KDIGO clinical practice guidelines for the diagnosis, evaluation, prevention, and treatment of mineral and bone disorders in chronic kidney disease. Pol Arch Med Wewn. 2010; 120: 300-306.
2. Klavansky S, Komaroff E, Cavanaugh PF, et al. Relationship between age, renal function and bone mineral density in the US population. Osteoporosis Int. 2003; 14: 570-576.
3. Ishani A, Blackwell T, Jamal SA, et al.; MORE Investigators. The effect of raloxifene treatment in postmenopausal women with CKD. J Am Soc Nephrol. 2008; 19: 1430-1438.
4. Jamal SA, Bauer DC, Ensrud KE, et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. J Bone Miner Res. 2007; 22: 503-508.
5. Miller PD, Roux C, Boonen S, et al. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. J Bone Miner Res. 2005; 20: 2105-2015.
6. Miller PD, Schwartz EN, Chen P, et al. Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporos Int. 2007; 18: 59-68.
7. Alem AM, Sherrard DJ, Gillen DL, et al. Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int. 2000; 58: 396-399.
8. Jadoul M, Albert JM, Akiba T, et al. Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2006; 70: 1358-1366.
9. Dooley AC, Weiss NS, Kestenbaum B. Increased risk of hip fracture among men with CKD. Am J Kidney Dis. 2008; 51: 38-44.
10. Nickolas TJ, McMahon DJ, Shane E. Relationship between moderate to severe kidney disease and hip fracture in the United States. J Am Soc Nephrol. 2006; 17: 3223-3232.
11. Ensrud KE, Lui LY, Taylor BC, et al.; Osteoporotic Fractures Research Group. Renal function and risk of hip and vertebral fractures in older women. Arch Intern Med. 2007; 167: 133-139.
12. Kaji H, Yamauchi M, Yamaguchi T, et al. Mild renal dysfunction is a risk factor for a decrease in bone mineral density and vertebral fractures in Japanese postmenopausal women. J Clin Endocrinol Metabol. 2010; 95: 4635-4642.
13. Prigent A. Monitoring renal function and limitations of renal function tests. Semin Nucl Med. 2008; 38: 32-46.
14. Earley A, Miskulin D, Lamb EJ, et al. Estimating equations for glomerular filtration rate in the era of creatinine standardization: a systematic review. Ann Intern Med. 2012; 156: 785-795.
15. McCarthy JT, Rule AD, Achenbach SJ, et al. Use of renal function measurements for assessing fracture risk in postmenopausal women. Mayo Clin Proc. 2008; 83: 1231-1239.
16. Hsu CY, Cummings SR, McCulloch CE, Chertow GM. Bone mineral density is not diminished by mild to moderate chronic renal insufficiency. Kidney Int. 2002; 61: 1814-1820.
17. Jamal SA, Hayden JA, Beyene J. Low bone mineral density and fractures in long-Term hemodialysis patients: a meta-Analysis. Am J Kidney Dis. 2007; 49: 674-681.
18. Nickolas TL, Leonard MB, Shane E. Chronic kidney disease and bone fracture: a growing concern. Kidney Int. 2008; 74: 721-731.
19. Cejka D, Patsch JM, Weber M, et al. Bone microarchitecture in hemodialysis patients assessed by HR-pQCT. Clin J Am Soc Nephrol. 2011; 6: 2264-2271.
20. Kanis JA, Kanis JA, Hans D, et al.; Task Force of the FRAX Initiative. Interpretation and use of FRAX in clinical practice. Osteoporos Int. 2011; 22: 2395-2411.
21. von der Recke P, Hansen MA, Hassager C. The association between low bone mass at the menopause and cardiovascular mortality. Am J Med. 1999; 106: 273-278.
22. Tankò LB, Bagger YZ, Christiansen C. Low bone mineral density in the hip as a marker of advanced atherosclerosis in elderly women. Calcif Tissue Int. 2003; 73: 15-20.
23. Schulz E, Arfai K, Liu X, et al. Aortic calcification and the risk of osteoporosis and fractures. J Clin Endocrinol Metab. 2004; 89: 4246-4253.
24. Hirose K, Tomiyama H, Okazaki R, et al. Increased pulse wave velocity associated with reduced calcaneal quantitative osteo-sono index: possible relationship between atherosclerosis and osteopenia. J Clin Endocrinol Metab. 2003; 88: 2573-2578.
25. Taal MW, Rose S, Masud T, et al. Total hip bone mass predicts survival in chronic hemodialysis patients. Kidney Int. 2003; 63: 1116-1120.
26. Rodríguez-García M, Gómez-Alonso C, Naves-Díaz M, et al. Vascular calcifications, vertebral fractures and mortality in haemodialysis patients. Nephrol Dial Transplant. 2009; 24: 239-246.
27. London GM. Bone-vascular axis in chronic kidney disease: a reality? Clin J Am Soc Nephrol. 2009; 4: 254-257.
28. Stompór T, Pasowicz M, Sulowicz W, et al. Trends and dynamics of changes in calcification score over the 1-year observation period in patients on peritoneal dialysis. Am J Kidney Dis. 2004; 44: 517-28.
29. Goodman WG, Goldin J, Kuizon BD, et al. Coronary-Artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000; 342: 1478-1483.
30. Panuccio V, Tripepi R, Tripepi G, et al. Heart valve calcifications, survival, and cardiovascular risk in hemodialysis patients. Am J Kidney Dis. 2004; 43: 479-484.
31. Braun J, Oldendorf M, Moshage W, et al. Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis. 1996; 27: 394-401.
32. London GM, Marty C, Marchais SJ, et al. Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol. 2004; 15: 1943-1951.
33. Braun J. Extraosseous calcification in patients with chronic renal failure-no escape? Nephrol Dial Transplant. 2005; 20: 2054-2059.
34. Stompór T. An overview of the pathophysiology of vascular calcification in chronic kidney disease. Perit Dial Int. 2007; 27 Suppl 2: S215-S222.
35. Shanahan CM, Crouthamel MH, Kapustin A, Giachelli CM. Arterial calcification in chronic kidney disease: key roles for calcium and phosphate. Circ Res. 2011; 109: 697-711.
36. Koshiyama H, Nakamura Y, Tanaka S, Minamikawa J. Decrease in carotid intima-media thickness after 1-year therapy with etidronate for osteopenia associated with type 2 diabetes. J Clin Endocrinol Metab. 2000; 85: 2793-2796.
37. Nitta K, Akiba T, Suzuki K, et al. Effects of cyclic intermittent etidronate therapy on coronary artery calcification in patients receiving long-Term hemodialysis. Am J Kidney Dis. 2004; 44: 680-688.
38. Matuszkiewicz-Rowińska J, Skórzewska K, Radowicki S, et al. The benefits of hormone replacement therapy in pre-menopausal women with oestrogen deficiency on haemodialysis. Nephrol Dial Transplant. 1999; 14: 1238-1243.
39. Black DM, Thompson DE, Bauer DC, et al.; Fracture Intervention Trial. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab. 2000; 85: 4118-4124.
40. Perazella MA, Markowitz GS. Bisphosphonate nephrotoxicity. Kidney Int. 2008; 74: 1385-1393.
41. Henrich DM, Hoffmann M, Uppenkamp M, Bergner R. Tolerability of dose escalation of ibandronate in patients with multiple myeloma and end-stage renal disease: a case series. Onkologie. 2009; 32: 482-486.
42. Diel IJ, Weide R, Köppler H, et al. Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records review. Support Care Cancer. 2009; 17: 719-725.
43. Elmariah S, Delaney JA, O'Brien KD, et al. Bisphosphonate Use and Prevalence of Valvular and Vascular Calcification in Women MESA (The Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2010; 56: 1752-1759.
44. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001; 344: 1434-1441.
45. Boyce BF, Xing L. Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys. 2008; 473: 139-146.
46. Hanada R, Hanada T, Penninger JM. Physiology and pathophysiology of the RANKL/RANK system. Biol Chem. 2010; 391: 1365-1370.
47. Jules J, Ashley JW, Feng X. Selective targeting of RANK signaling pathways as new therapeutic strategies for osteoporosis. Expert Opin Ther Targets. 2010; 14: 923-934.
48. Cummings SR, San Martin J, McClung MR, et al.; FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009; 361: 756-765.
49. Jamal SA, Ljunggren O, Stehman-Breen C, et al. Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res. 2011; 26: 1829-1835.